Skip to content

Clinical study on complications, influencing factors,and long-term prognosis of PBC

Clinical study on complications, influencing factors,and long-term prognosis of PBC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111091
Enrollment
Unknown
Registered
2025-10-24
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Biliary Cholangitis, PBC

Interventions

Case group:None
Control group:None

Sponsors

Beijing Ditan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Case group: Collected patients with PBC admitted to Beijing Ditan Hospital from 2008 to 2023 as the case group. Inclusion criteria: (1). Primary biliary cholangitis or cirrhosis;(2). Age >= 18 years. 2. Control group: Collected patients with chronic hepatitis B-related cirrhosis admitted to Beijing Ditan Hospital from 2008 to 2023 as the control group. Inclusion criteria: (1). Chronic hepatitis B-related cirrhosis; (2). Age >= 18 years.

Exclusion criteria

Exclusion criteria: 1.Exclusion criteria for the case group: (1).Exclusion of viral hepatitis and cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune hepatitis and cirrhosis, drug-induced liver injury, Wilson’s disease, primary sclerosing cholangitis, hepatic sinusoidal obstruction syndrome, Budd-Chiari syndrome, or other liver diseases; (2). Exclusion of malignant tumors other than hepatocellular carcinoma, and severe cardiopulmonary diseases; (3). Incomplete clinical data. 2.Exclusion criteria for the control group: (1). Exclusion of viral hepatitis and cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune hepatitis and cirrhosis, drug-induced liver injury, Wilson’s disease, primary sclerosing cholangitis, hepatic sinusoidal obstruction syndrome, Budd-Chiari syndrome, or other liver diseases; (2). Exclusion of malignant tumors other than hepatocellular carcinoma, severe cardiopulmonary diseases; (3). Incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Esophagogastric variceal bleeding;

Secondary

MeasureTime frame
Hepatocellular carcinoma;Portal vein thrombosis, PVT;Prognosis;

Countries

China

Contacts

Public ContactDeng Caihong

Beijing Ditan Hospital, Capital Medical University

dch@ccmu.edu.cn+86 10 8432 2309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026